Irinotecan (CPT-11): Recent Developments and Future Directions—Colorectal Cancer and Beyond

Irinotecan (CPT-11): Recent Developments and Future Directions–Colorectal Cancer and Beyond Mace L. Rothenberg Oncologist 2001; 6: 66-80 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in gastrointestinal cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Gain insights into irinotecan's pharmacology, metabolism, mechanisms of resistance, and molecular determinants of response. Understand the development of irinotecan from its early evaluation of single-agent in refractory disease settings to evaluation of front-line irinotecan-based combination chemotherapy regimens. Appreciate how irinotecan's activity lends itself to the treatment of a number of malignancies. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Feb. 13, 2002 Most Recent Review: Nov. 15, 2005* Most Recent Update: Feb. 13, 2002 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.